At ESGCT, Precigen Data Supports Its Lead Candidate as RRP Treatment ; Company joins Inovio in presenting positive clinical results, with FDA waiving Phase III trial requirement for both
In: GEN Edge, Jg. 5 (2023), Heft 1, S. 761-767
academicJournal
Zugriff:
Titel: |
At ESGCT, Precigen Data Supports Its Lead Candidate as RRP Treatment ; Company joins Inovio in presenting positive clinical results, with FDA waiving Phase III trial requirement for both
|
---|---|
Autor/in / Beteiligte Person: | Philippidis, Alex |
Link: | |
Zeitschrift: | GEN Edge, Jg. 5 (2023), Heft 1, S. 761-767 |
Veröffentlichung: | Mary Ann Liebert Inc, 2023 |
Medientyp: | academicJournal |
ISSN: | 2768-1580 |
DOI: | 10.1089/genedge.5.1.146 |
Sonstiges: |
|